Skip to Content

T. Rowe Price Health Sciences PRHSX

Analyst rating as of
NAV / 1-Day Return
104.19  /  0.16 %
Total Assets
18.4 Bil
Adj. Expense Ratio
0.760%
Expense Ratio
0.760%
Fee Level
Low
Longest Manager Tenure
4.79 years
Category
Health
Investment Style
Large Growth
Min. Initial Investment
2,500
Status
Open
TTM Yield
0.00%
Turnover
39%
Premium

Morningstar’s Analysis

Will PRHSX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

T. Rowe Price’s New Entity Brings Opportunities and Trade-Offs

Analyst Note

| |

T. Rowe Price Group TROW announced on Nov. 19 that it plans to split its investment-research organization in two with the launch of T. Rowe Price Investment Management in 2022’s second quarter. Six existing strategies and supporting analytical resources will move to the new entity, and this cohort will remain entirely separate from the legacy T. Rowe Price Associates; the two teams will not share research or investment resources once divided.

Unlock our full analysis with Morningstar Premium